BioSyent Signs Exclusive Agreement for New Women’s Health Product
October 01 2020 - 8:25AM
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce
that its subsidiary, BioSyent Pharma Inc., has signed an exclusive
License and Supply Agreement with a European partner for a new
product in the women’s health market for Canada. The product has
been approved for sale in Canada, the U.S.A., Europe and in several
other markets around the world. BioSyent intends to
launch the product to the Canadian market in Q2 2021.
“We are pleased to add this new gynecology
product to our growing portfolio of women’s health products,
including Tibella®, FeraMAX®, and RepaGyn®,” said René Goehrum,
President and CEO of BioSyent. “We continue to deliver on our goal
to bring products to Canada that are unique, differentiated and
treat unmet medical needs. This new product is an excellent fit
with the healthcare practitioners and patients we currently serve
with our Women’s Health franchise and also adds a new group of
customers managing infertility issues. As the new product is
already approved, we can significantly shorten the time to
launch.”
About BioSyent
Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community,
specialty/hospital, and international business units.
As of the date of this press release, the
Company has 12,808,600 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein
represent our judgment, as at the release date, and are subject to
risks and uncertainties that may cause actual results or outcomes
to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited
to, those associated with clinical trials, product development,
future revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024